Cargando…

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders

Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, Austin, Vanleuven, Jordan, Perekopskiy, David, Liu, Dewey, Xu, Desiree, Alzayat, Omar, Elgokhy, Taiseer, Do, Timothy, Gann, Meghan, Martin, Ryan, Liu, Da-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784968/
https://www.ncbi.nlm.nih.gov/pubmed/36558997
http://dx.doi.org/10.3390/ph15121546
_version_ 1784857938762924032
author Lui, Austin
Vanleuven, Jordan
Perekopskiy, David
Liu, Dewey
Xu, Desiree
Alzayat, Omar
Elgokhy, Taiseer
Do, Timothy
Gann, Meghan
Martin, Ryan
Liu, Da-Zhi
author_facet Lui, Austin
Vanleuven, Jordan
Perekopskiy, David
Liu, Dewey
Xu, Desiree
Alzayat, Omar
Elgokhy, Taiseer
Do, Timothy
Gann, Meghan
Martin, Ryan
Liu, Da-Zhi
author_sort Lui, Austin
collection PubMed
description Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments.
format Online
Article
Text
id pubmed-9784968
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97849682022-12-24 FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders Lui, Austin Vanleuven, Jordan Perekopskiy, David Liu, Dewey Xu, Desiree Alzayat, Omar Elgokhy, Taiseer Do, Timothy Gann, Meghan Martin, Ryan Liu, Da-Zhi Pharmaceuticals (Basel) Review Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments. MDPI 2022-12-13 /pmc/articles/PMC9784968/ /pubmed/36558997 http://dx.doi.org/10.3390/ph15121546 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lui, Austin
Vanleuven, Jordan
Perekopskiy, David
Liu, Dewey
Xu, Desiree
Alzayat, Omar
Elgokhy, Taiseer
Do, Timothy
Gann, Meghan
Martin, Ryan
Liu, Da-Zhi
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title_full FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title_fullStr FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title_full_unstemmed FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title_short FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
title_sort fda-approved kinase inhibitors in preclinical and clinical trials for neurological disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784968/
https://www.ncbi.nlm.nih.gov/pubmed/36558997
http://dx.doi.org/10.3390/ph15121546
work_keys_str_mv AT luiaustin fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT vanleuvenjordan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT perekopskiydavid fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT liudewey fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT xudesiree fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT alzayatomar fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT elgokhytaiseer fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT dotimothy fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT gannmeghan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT martinryan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders
AT liudazhi fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders